{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-352233","form_type":"8-K/A","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2026-08-14T20:10:15+00:00","discovered_at":"2026-08-14T20:17:33.330868+00:00","generated_at":"2026-08-14T20:18:00.938848+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"NewAmsterdam Pharma details COO Kling's exit: unvested equity canceled, $50k/mo advisor fee","bullets":["Douglas Kling resigned as COO effective Aug 14, 2026, to become CEO of another clinical-stage biotech.","Unvested stock options and RSUs canceled as of separation date, except those vesting on continued service through May 14, 2027.","Kling entered Advisor Agreement with NewAmsterdam Pharma B.V. for $50,000/month plus expenses for PREVAIL trial and other clinical programs.","Advisor Agreement runs to May 14, 2027; includes confidentiality, non-disparagement, non-solicitation covenants."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-352233","json":"https://secwatch.observer/filing/0001193125-26-352233.json","markdown":"https://secwatch.observer/filing/0001193125-26-352233.md","text":"https://secwatch.observer/filing/0001193125-26-352233.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526352233/0001193125-26-352233-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526352233/nams-20260716.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T20:18:00.938848+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}